114 related articles for article (PubMed ID: 37695697)
1. Carrier-Free Nanovaccine: An Innovative Strategy for Ultrahigh Melanoma Neoantigen Loading.
Zeng T; Zang W; Xiao H; Jiang Y; Lin S; Wang M; Li S; Li L; Li C; Lu C; Yang H
ACS Nano; 2023 Sep; 17(18):18114-18127. PubMed ID: 37695697
[TBL] [Abstract][Full Text] [Related]
2. Programming peptide-oligonucleotide nano-assembly for engineering of neoantigen vaccine with potent immunogenicity.
Xiang Z; Lu J; Rao S; Fu C; Yao Y; Yi Y; Ming Y; Sun W; Guo W; Chen X
Theranostics; 2024; 14(6):2290-2303. PubMed ID: 38646651
[No Abstract] [Full Text] [Related]
3. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
4. Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy.
Liang Z; Cui X; Yang L; Hu Q; Li D; Zhang X; Han L; Shi S; Shen Y; Zhao W; Ju Q; Deng X; Wu Y; Sheng W
Int J Pharm; 2021 Oct; 608():121091. PubMed ID: 34555477
[TBL] [Abstract][Full Text] [Related]
5. Engineering a HemoMap Nanovaccine for Inducing Immune Responses against Melanoma.
Dai H; Huang Y; Guo J; Li L; Ke Y; Cen L; Meng F; Chen X; Liu B; Qian X
ACS Appl Mater Interfaces; 2022 Nov; 14(47):52634-52642. PubMed ID: 36383430
[TBL] [Abstract][Full Text] [Related]
6. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine.
Liu D; Deng B; Liu Z; Ma B; Leng X; Kong D; Ji T; Liu L
Nano Lett; 2021 May; 21(9):3965-3973. PubMed ID: 33886338
[TBL] [Abstract][Full Text] [Related]
8. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
[TBL] [Abstract][Full Text] [Related]
9. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
[TBL] [Abstract][Full Text] [Related]
10. Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.
Chu Y; Qian L; Ke Y; Feng X; Chen X; Liu F; Yu L; Zhang L; Tao Y; Xu R; Wei J; Liu B; Liu Q
J Nanobiotechnology; 2022 Apr; 20(1):190. PubMed ID: 35418151
[TBL] [Abstract][Full Text] [Related]
11. Sulfonium-Driven Neoantigen-Released DNA Nanodevice as a Precise Vaccine for Tumor Immunotherapy and Prevention.
Zhang Y; Xu H; Jiang L; Liu Z; Lian C; Ding X; Wan C; Liu N; Wang Y; Yu Z; Zhu L; Yin F; Li Z
ACS Nano; 2022 Nov; 16(11):19509-19522. PubMed ID: 36318615
[TBL] [Abstract][Full Text] [Related]
12. "Minimalist" Nanovaccine Constituted from Near Whole Antigen for Cancer Immunotherapy.
Wang K; Wen S; He L; Li A; Li Y; Dong H; Li W; Ren T; Shi D; Li Y
ACS Nano; 2018 Jul; 12(7):6398-6409. PubMed ID: 29927574
[TBL] [Abstract][Full Text] [Related]
13. A dual-adjuvant neoantigen nanovaccine loaded with imiquimod and magnesium enhances anti-tumor immune responses of melanoma.
Chen X; Cen L; Liu Q; Chu Y; Feng X; Ke Y; Zhang Z; Dai H; Huang S; Liu B; Qian X
Biomater Sci; 2022 Nov; 10(23):6740-6748. PubMed ID: 36285738
[TBL] [Abstract][Full Text] [Related]
14. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies.
Li J; Li J; Peng Y; Du Y; Yang Z; Qi X
J Control Release; 2023 Jan; 353():423-433. PubMed ID: 36470333
[TBL] [Abstract][Full Text] [Related]
16. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
[TBL] [Abstract][Full Text] [Related]
17. Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy.
Dong Y; Gao J; Pei M; Wang X; Zhang C; Du Y; Jiang Y
Int J Nanomedicine; 2020; 15():2685-2697. PubMed ID: 32368049
[TBL] [Abstract][Full Text] [Related]
18. Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report.
Shao J; Liu Q; Shen J; Qian X; Yan J; Zhu Y; Qiu X; Lu C; Cen L; Tian M; Du J; Liu B
Front Immunol; 2022; 13():799026. PubMed ID: 35273594
[TBL] [Abstract][Full Text] [Related]
19. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase.
Guan X; Chen J; Hu Y; Lin L; Sun P; Tian H; Chen X
Biomaterials; 2018 Jul; 171():198-206. PubMed ID: 29698869
[TBL] [Abstract][Full Text] [Related]
20. A Potent Micron Neoantigen Tumor Vaccine GP-Neoantigen Induces Robust Antitumor Activity in Multiple Tumor Models.
Jing Z; Wang S; Xu K; Tang Q; Li W; Zheng W; Shi H; Su K; Liu Y; Hong Z
Adv Sci (Weinh); 2022 Aug; 9(24):e2201496. PubMed ID: 35712770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
